Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Surveillance of Patients With Suspected Acute Myocardial Infarction That Receive Early Inhospital Thrombolysis With Metalyse

Completed

Conditions: Myocardial Infarction

Interventions: Drug: Metalyse weight-adjusted

First Posted Date: 2014-07-18

Last Posted Date: 2014-07-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 351

Registration Number: NCT02194153

Efficacy and Tolerability of a Bilberry Extract in Volunteers With Impaired Twilight and Night Vision

Phase 2

Completed

Conditions: Healthy

Interventions: Drug: Anthocyan capsules
Drug: Placebo

First Posted Date: 2014-07-18

Last Posted Date: 2014-07-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 195

Registration Number: NCT02194127

Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIBN 4096 BS in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBN 4096 BS - in single rising doses
Drug: Placebo

First Posted Date: 2014-07-18

Last Posted Date: 2014-07-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT02194335

Comparison of Safety and Efficacy of COMBIVENT HFA to COMBIVENT (CFC) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Terminated

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: COMBIVENT CFC
Drug: COMBIVENT HFA
Drug: Placebo CFC
Drug: Placebo HFA

First Posted Date: 2014-07-18

Last Posted Date: 2014-07-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 360

Registration Number: NCT02194205

Safety, Tolerability and Pharmacokinetics After Administration of Increasing Dose of BIBN 4096 BS in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBN 4096 BS - in single rising doses
Drug: Placebo

First Posted Date: 2014-07-18

Last Posted Date: 2014-07-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 38

Registration Number: NCT02194322

Safety, Tolerability and Pharmacokinetics of Inhalative Administration of BIBN 4096 BS in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBN 4096 BS - in single rising doses
Drug: Placebo

First Posted Date: 2014-07-18

Last Posted Date: 2014-07-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT02194777

Study to Evaluate Safety, Tolerability and Pharmacokinetics of Increasing Repeated Oral Doses of Ambroxol Lozenges in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ambroxol - in single rising doses
Drug: Placebo

First Posted Date: 2014-07-18

Last Posted Date: 2014-07-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 34

Registration Number: NCT02194283

Pharmacokinetic Properties of Nevirapine Extended Release Tablets When Administered Orally in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Nevirapine, low dose
Drug: Nevirapine, high dose

First Posted Date: 2014-07-18

Last Posted Date: 2014-07-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT02194218

Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Viramune® in HIV-1 Infected Subjects

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: NVP XR 400 mg (KCR 25%)
Drug: NVP XR 300 mg (KCR 20%)
Drug: NVP XR 300 mg (KCR 25%)
Drug: NVP XR 400 mg (KCR 20%)
Drug: NVP IR 200 mg (Viramune®)
Other: high-fat breakfast

First Posted Date: 2014-07-18

Last Posted Date: 2014-07-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 92

Registration Number: NCT02194179

Relative Bioavailability of Ambroxol Hydrochloride Lozenge in Comparison to Ambroxol Hydrochloride Syrup (Mucosolvan®) in Healthy Female and Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ambroxol hydrochloride - syrup
Drug: Ambroxol hydrochloride - lozenge

First Posted Date: 2014-07-18

Last Posted Date: 2014-07-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02194296

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy